June 30, 2021
Grifols announces a strategic investment from GIC of USD 1 billion
- GIC will invest approximately USD 1 billion to acquire a minority stake in Grifols’ US subsidiary Biomat USA, which manages 296 U.S.-based plasma collection centers.
- Grifols will maintain control over Biomat’s management and operations, and all plasma collected by Biomat will continue to be supplied to Grifols to produce its plasma-derived medicines.
- All proceeds from the investment will be used to repay debt, reflecting Grifols’ firm commitment to reduce its leverage levels.
- This transaction supports Grifols’ strategy to expand and strengthen its U.S. plasma center network.
Barcelona, June 30, 2021.- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare leader with a track record of more than 100 years dedicated to enhancing people’s health and well-being and a forerunner in plasma-derived medicines, transfusion diagnostics and hospital pharmacy solutions, and GIC, the sovereign wealth fund of Singapore, have entered into a definitive agreement under which GIC will invest ~USD 1 billion in Grifols’ wholly-owned US subsidiary Biomat USA. As part of the transaction, GIC will become a strategic investor in Grifols’ business, holding a minority stake in Biomat USA through the acquisition of newly issued non-voting stock.
Biomat is a global leader in plasma collection, with a network of 296 U.S.-based plasma collection centers.
Grifols will continue to oversee all aspects of Biomat’s management and operations. All plasma collected by Biomat and its subsidiaries will continue to be supplied to Grifols for the production of plasma-derived medicines, through a long-term plasma supply agreement.
Grifols’ leadership in the manufacture of plasma-based medicines, extensive expertise in the expansion and management of plasma centers, market know-how, and outstanding reputation were all key factors in GIC’s decision to invest in the company.
As Grifols’ co-CEO Víctor Grífols Deu notes, “We are pleased to welcome GIC as a strategic investor to bolster and expand our U.S. plasma center network, which is a clear competitive advantage. This transaction supports Grifols’ business model and our strategy in plasma collection, together with a solid innovation portfolio focused on disease management beyond the therapies based on plasma-derived medicines. With robust demand for Grifols’ plasma proteins, our efforts remain centered on doing our best to respond to the needs of patients and healthcare professionals.”
Grifols will apply all proceeds from GIC’s investment to repay debt as part of its ongoing commitment to gradually reduce financial leverage. In the first quarter of 2021, Grifols’ net financial debt totaled EUR 6,200.5 million1 and its net financial debt/ EBITDA ratio was 5.1x following the acquisitions of plasma centers from BPL and Kedrion and Grifols’ transaction with GigaGen.
The closing of GIC’s strategic investment in Grifols is subject to certain conditions, including applicable regulatory authorizations, such as the Committee on Foreign Investment in the United States (CFIUS).
Grifols retained Osborne Clarke, S.L.P and Proskauer Rose, L.L.P as legal advisors for the transaction, and Nomura Securities International, Inc. as sole financial advisor. GIC retained Dechert LLP as legal advisor.
1Excluding the impact of IFRS 16